Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)

Beijing Tiantan Biological Products Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,805	4,555	3,713	4,330	1,748	1,413
Cash & Short-Term Investments	4,805	4,555	3,713	4,330	1,748	1,413
Cash Growth	-5.05%	22.68%	-14.25%	147.68%	23.69%	13.11%
Accounts Receivable	262.19	94.13	1,173	1,027	695.59	636.47
Other Receivables	20.53	39.08	28.36	22.27	16.93	22.75
Receivables	282.73	133.21	1,201	1,050	712.52	659.22
Inventory	3,408	2,844	2,332	2,144	2,172	1,949
Other Current Assets	46.36	36.53	24.87	22.27	23.64	24.32
Total Current Assets	8,542	7,569	7,271	7,546	4,656	4,046
Property, Plant & Equipment	5,223	4,886	4,055	2,631	1,997	1,560
Long-Term Investments	143.2	146.06	146.06	146.06	121.59	106.59
Goodwill	173.92	173.92	173.92	127.93	115.01	115.01
Other Intangible Assets	743.87	686.88	441.63	370.99	252.44	293.21
Long-Term Deferred Tax Assets	43.35	46.74	60.63	67.01	63.11	53.79
Long-Term Deferred Charges	479.9	470.26	552.69	362.46	174.08	61.63
Other Long-Term Assets	204.22	208.66	228.88	326.85	161.34	78.03
Total Assets	15,554	14,188	12,929	11,578	7,541	6,314
Accounts Payable	94.15	179.1	69.39	73.7	45.86	49.94
Accrued Expenses	340.18	168.69	163.21	150.02	146.85	40.17
Short-Term Debt	-	-	-	-	200.13	-
Current Portion of Long-Term Debt	-	-	112.99	108.15	126.25	-
Current Portion of Leases	11.24	17.95	10.82	16.51	-	-
Current Income Taxes Payable	121.74	61.85	73.79	44.86	36.63	40.19
Current Unearned Revenue	423.76	357.26	292.72	215.31	200.66	154.71
Other Current Liabilities	560.3	494.78	434.44	201.03	182.98	366.93
Total Current Liabilities	1,551	1,280	1,157	809.58	939.36	651.94
Long-Term Debt	-	-	253.75	366.25	474.59	400.6
Long-Term Leases	28.01	24.42	25.62	18.01	-	-
Long-Term Unearned Revenue	97.19	99.56	101.9	92.69	80.83	73.55
Long-Term Deferred Tax Liabilities	27.2	28.85	30.87	20.14	11.15	9.69
Other Long-Term Liabilities	1.24	1.24	4.1	4.1	4.1	1.26
Total Liabilities	1,705	1,434	1,574	1,311	1,510	1,137
Common Stock	1,977	1,648	1,648	1,373	1,254	1,045
Additional Paid-In Capital	2,463	2,793	2,793	3,067	274.62	274.62
Retained Earnings	6,201	5,382	4,355	3,612	2,989	2,619
Comprehensive Income & Other	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Total Common Equity	10,641	9,823	8,795	8,052	4,518	3,939
Minority Interest	3,207	2,932	2,560	2,215	1,513	1,238
Shareholders' Equity	13,849	12,754	11,356	10,267	6,031	5,177
Total Liabilities & Equity	15,554	14,188	12,929	11,578	7,541	6,314
Total Debt	39.25	42.37	403.17	508.92	800.97	400.6
Net Cash (Debt)	4,766	4,513	3,310	3,821	947.15	1,013
Net Cash Growth	-1.53%	36.34%	-13.38%	303.40%	-6.48%	-0.58%
Net Cash Per Share	2.39	2.27	1.66	1.97	0.52	0.56
Filing Date Shares Outstanding	1,977	1,977	1,977	1,977	1,806	1,806
Total Common Shares Outstanding	1,977	1,977	1,977	1,977	1,806	1,806
Working Capital	6,991	6,290	6,113	6,736	3,717	3,394
Book Value Per Share	5.38	4.97	4.45	4.07	2.50	2.18
Tangible Book Value	9,723	8,962	8,180	7,553	4,150	3,531
Tangible Book Value Per Share	4.92	4.53	4.14	3.82	2.30	1.95
Buildings	-	2,241	1,957	963.02	949.32	800.52
Machinery	-	2,218	1,996	1,258	1,177	1,082
Construction In Progress	-	2,044	1,532	1,623	1,030	739.97

Source: S&P Capital IQ. Standard template. Financial Sources.